Company / Operating Cash Flow per Share
GYRE THERAPEUTICS, INC. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$0.01
FY2025
5-year range
-$3.79 / $0.17
FY2021-FY2025
Trend
+124.6%
vs FY2024
Sector context
#74 of 212
Health Care
What the data says
At $0.01, GYRE THERAPEUTICS, INC.'s operating cash flow per share ranks #74 of 212 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-23.71 in FY2016 to $0.17 in FY2023.
Based on SEC 10-K filings.
0.01 in FY2025 with a 3-year CAGR of -56.4%.
Declined from $0.17 to $0.01 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -56.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-99.8% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 124.6% year-over-year.
- Ranks #74 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2023.
- Lowest operating cash flow per share in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.01 | +124.6% |
| FY2024 | -$0.05 | -128.3% |
| FY2023 | $0.17 | +19.0% |
| FY2022 | $0.14 | +103.7% |
| FY2021 | -$3.79 | -4.6% |
| FY2020 | -$3.62 | +0.7% |
| FY2019 | -$3.65 | -11.3% |
| FY2018 | -$3.28 | +43.7% |
| FY2017 | -$5.82 | +75.4% |
| FY2016 | -$23.71 | +63.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026